Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on Wednesday, May 13, at an average price of $578.65, totaling about $5.5 million. After the sale, she still owned 40,513 shares, a 19% reduction in her position.
- The company recently reported earnings below expectations, posting $5.82 EPS versus the $7.00 consensus estimate. Revenue also came in slightly light at $781.5 million, down 1.6% year over year.
- Despite the insider sale and mixed earnings, Wall Street remains constructive on UTHR, with 11 Buy ratings and 2 Hold ratings. The stock’s consensus target price is $619.42, above its recent trading level.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $578.65, for a total transaction of $5,497,175.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at approximately $23,442,847.45. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Price Performance
Shares of UTHR opened at $575.79 on Friday. The firm has a 50-day moving average of $556.50 and a 200-day moving average of $506.65. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a market cap of $24.44 billion, a PE ratio of 21.25, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the business earned $6.63 EPS. The business's revenue was down 1.6% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 27.64 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on UTHR shares. HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective for the company. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $619.42.
Read Our Latest Research Report on UTHR
Institutional Trading of United Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP boosted its holdings in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its holdings in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after buying an additional 295,221 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock worth $387,801,000 after buying an additional 341,383 shares during the period. Finally, Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $317,617,000. Institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
